ArticleBlood research2023

A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.

Seok Jin Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.